lymphoma

[BMC Cancer] Researchers observed tumor formation in NOD SCID mice after a single subcutaneous injection of human umbilical cord-MSCs and the effect of these cells on tumor growth in tumor-bearing mice.

[Blood] The authors reported the first German real-world data on standard-of-care CAR-T cell therapies with the aim to explore risk factors associated with outcome.

[Wugen, Inc.] Wugen, Inc. announced that the first patient has been dosed in a Phase I/II trial of WU-CART-007 for the treatment of relapsed or refractory T cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma.

[Modern Pathology] Ten patients had a history of B cell malignancies, one each of myeloid neoplasm, breast or prostate cancer, and four others had underlying immune disorders. Most patients died, mostly of disease, with a median overall survival of 12.7 months.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that proportional flux in the levels of aryl hydrocarbon receptor (AhR) nuclear translocator isoforms 1 and 3 modulated AhR signaling in terms of amplitude and expression of distinct gene programs.

[npj Precision Oncology] Investigators established lorlatinib intermediate resistant cells from a patient-derived cell model. Glycogen synthase kinase 3 (GSK3) inhibitions significantly suppressed lorlatinib intermediate resistant cell growth.